首页 | 本学科首页   官方微博 | 高级检索  
     

地塞米松降低紫杉醇对肺癌细胞化疗作用的实验研究
引用本文:高雅茹,王玮,袁夏,贾婷婷,张蝶,袁易,曾海荣. 地塞米松降低紫杉醇对肺癌细胞化疗作用的实验研究[J]. 中国药理学通报, 2019, 0(3): 382-387
作者姓名:高雅茹  王玮  袁夏  贾婷婷  张蝶  袁易  曾海荣
作者单位:1.上海中医药大学附属普陀医院药学部
基金项目:国家自然科学基金资助项目(No 81703880);上海市普陀区中心医院临床药学重点专科(No 2016107A)
摘    要:目的研究地塞米松(dexamethasone,Dex)降低紫杉醇对肺癌细胞的化疗作用。方法 MTT法考察不同浓度的紫杉醇,以及地塞米松(10μmol·L-1)与不同浓度的紫杉醇联用,对肺癌细胞A549、Calu-1存活率的影响;流式细胞仪检测细胞周期;Western blot检测地塞米松对糖皮质激素受体(GR)、P-糖蛋白(P-gP)、多药耐药蛋白1(MRP-1)表达的影响;裸鼠移植瘤实验考察地塞米松降低紫杉醇对肺癌细胞的化疗作用。结果与紫杉醇单独作用相比,地塞米松(10μmol·L-1)联合紫杉醇降低了紫杉醇对肺癌细胞A549、Calu-1的敏感性,使IC50明显提高(A549细胞:IC50由0.58μmol·L-1提高到1.35μmol·L-1;Calu-1细胞:IC50由1.10μmol·L-1提高到2.10μmol·L-1);地塞米松使GR蛋白表达增高,同时使P-gP、MRP-1蛋白的表达明显升高;地塞米松联合紫杉醇明显降低紫杉醇对裸鼠移植瘤的抑瘤效果。结论地塞米松联合紫杉醇可能使肺癌细胞产生耐药性,降低紫杉醇的化疗效果。

关 键 词:地塞米松  紫杉醇  联合用药  肺癌  化疗  多药耐药  糖皮质激素受体  P-糖蛋白

The experimental research of dexamethasone reducing paclitaxel chemotherapy on lung cancer cells
GAO Ya-ru,WANG Wei,YUAN Xia,JIA Ting-ting,ZHANG Die,YUAN Yi,ZENG Hai-rong. The experimental research of dexamethasone reducing paclitaxel chemotherapy on lung cancer cells[J]. Chinese Pharmacological Bulletin, 2019, 0(3): 382-387
Authors:GAO Ya-ru  WANG Wei  YUAN Xia  JIA Ting-ting  ZHANG Die  YUAN Yi  ZENG Hai-rong
Affiliation:(Pharmacy Dept,Putuo Hospital,Shanghai University of Traditional Chinese Medicine,Shanghai200062,China)
Abstract:Aim To investigate the effect of dexamethasone on paclitaxel chemotherapy,when given before chemotherapy.Methods MTT method was used to investigate the effects of paclitaxel at different concentrations and dexamethasone(10μmol·L^-1)combined with paclitaxel at indicate dosages on the cell viability of lung cancer cells A549 and Calu-1.The cell cycle was detected by flow cytometry.The effect of dexamethasone on protein expression of glucocorticoid receptor(GR),P-glycoprotein(P-gP)and multidrug resistance protein-1(MRP-1)expression were detected by Western blot.The effect of dexamethasone on lung cancer resistance of paclitaxel xenografts in nude mice was studied as well.Results paclitaxel at indicate dosages with dexamethasone(10μmol·L^-1)showed significantly increased IC 50 value(A549:from 0.58 to 1.35μmol·L^-1;Calu-1 from 1.10 to 2.10μmol·L^-1).Dexamethasone activated GR,increased GR expression,and up-regulated the expression of P-gP and MRP-1.Dexamethasone combined with paclitaxel significantly decreased the antitumor effect of paclitaxel on nude mice transplanted tumor.Conclusions Giving dexamethasone before chemotherapy may cause resistance to cancer cells and reduce the effect of paclitaxel chemotherapy.
Keywords:dexamethasone  paclitaxel  drug combination  lung cancer  chemotherapy  multidrug resistance  glucocorticoid receptor  p-glycoprotein
本文献已被 维普 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号